Sebia announces FDA clearance for its Hydrashift 2/4 daratumumab assay

The in vitro diagnostic test, developed in collaboration with Janssen, allows for assessment of response in patients with multiple myeloma by mitigating potential interference induced by daratumumab


Sebia, a world leader in multiple myeloma diagnostics testing and monitoring, announces today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Hydrashift 2/4 daratumumab assay, intended to be used with Hydragel IF, for the qualitative detection of monoclonal proteins in human serum by immunofixation electrophoresis. This in vitro diagnostic (IVD) reagent mitigates the daratumumab-mediated interference seen in Immunofixation results for patients with multiple myeloma treated with DARZALEX® (daratumumab), a fully human monoclonal antibody that binds to CD38.

The Hydrashift 2/4 daratumumab Immunofixation assay is the result of a collaboration between Sebia (Paris, France) and Janssen Biotech, Inc. (Horsham, PA, Etats-Unis), to provide the clinical community with better tools to monitor patients with multiple myeloma in line with the International Myeloma Working Group’s (IMWG) latest recommendations. Sebia received development rights from Janssen and is the worldwide supplier of this assay. Sebia’s broad market coverage will enable patients receiving DARZALEX® in many countries throughout the world to have access to testing. The assay received the CE Mark in November 2016.

Sebia is excited to have developed such a novel and innovative IVD assay,” said Jean-Marc Chermette, Sebia’s CEO. “Immunofixation is one of the tests referenced in the IMWG guidelines to assess complete response in a patient with multiple myeloma. This development confirms the company’s commitment and strategic objective to remain the market leader in providing the most advanced diagnostic tools supporting multiple myeloma disease management.”

The Hydrashift 2/4 daratumumab assay is performed on the Sebia Hydrasys 2 agarose gel platform. Sebia has a large established customer base utilizing this platform in academic centers, hospitals and reference laboratories across the world. The implementation of this assay will be easy and seamless in many of these institutions.

About multiple myeloma

Myeloma is the second most common blood cancer in the world. Globally, close to 230,000 people live with the disease. More than 110,000 new cases are diagnosed each year.

Download the press release: